-+ 0.00%
-+ 0.00%
-+ 0.00%
Zhitong Finance App News, ST Renfu (600079.SH) announced that the company's holding subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (“Yichang Renfu”, the company holds 80% of its shares) recently received the “Drug Clinical Trial Approval Notice” for midazolam nasal spray approved and issued by the State Drug Administration.
Share
Listen to the news
Zhitong Finance App News, ST Renfu (600079.SH) announced that the company's holding subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (“Yichang Renfu”, the company holds 80% of its shares) recently received the “Drug Clinical Trial Approval Notice” for midazolam nasal spray approved and issued by the State Drug Administration.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending